A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Study Name
	A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
ClinicalTrials.gov Identifier (if applicable)
	NCT05199584
Clinical Trial Category (check all that apply)
	Targeted Therapy
Study Center
Institution Name
	Endeavor Biomedicines
State
Country
	United States
List additional Institutions (include address, phone number, and website)
	Sites are located all across the United States, with the ability to open additional locations closer to a patient’s home.
Study Contacts
Principal Investigator
	Endeavor Clinical Trials
P.I. Phone
	(858) 727-3199
P.I. Email
	ebmclinical@endeavorbiomedicines.com
Study Coordinator
	Endeavor Clinical Trials
Study Coordinator Phone
	(858) 727-3199
Study Coordinator Email
	ebmclinical@endeavorbiomedicines.com
OVERVIEW – in layman’s terms (150 words max)
	The study drug, ENV-101, acts on a protein in the body that is thought to be involved with the growth of these abnormal cells caused by a mutation of a gene, PTCH1. By blocking this process, ENV-101 may slow the progress of the disease or you may have a partial or complete response.
More Information
	The Future of Cancer Treatments: How Next Generation Sequencing can Optimize Treatments – YouTube Website Patient Page xCures Landing Page Next-Generation Sequence Testing Brochure ENV-101 Brochure
Enrollment
	Ongoing
Study Start Date
	12/01/2021
Estimated Completion Date
	5/31/2024